Literature DB >> 15176497

Total and biologically active serum-soluble CD154 in patients with chronic idiopathic urticaria.

Jenny V Garmendia1, Mercedes Zabaleta, Isaac Blanca, Nicolás E Bianco, Juan B De Sanctis.   

Abstract

The pathogenesis of chronic idiopathic urticaria (CIU) is not understood completely; however, autoimmunity has been implicated. Because membrane and soluble forms of CD154 have been reported to be increased, in several autoimmune diseases, we have quantified the soluble CD154 (sCD154) molecule by a sandwich enzyme-linked immunosorbent assay in serum samples of 32 patients with CIU (aged 32 +/- 12 years) and compared them with 32 age- and sex-matched nonallergic controls. A marked increase was observed in patients with CIU as compared with controls (4.8 +/- 2.6 ng/mL versus 2.9 +/- 0.9 ng/mL; p < 0.0005). No significant differences were found between groups of patients with positive or negative autologous serum skin test. A biological assay to determine sCD154 showed that patients with positive autologous serum skin test have the highest levels (4.9 +/- 1.2 ng/mL) of biologically active sCD154 as compared with their negative counterparts (2.2 +/- 1.3 ng/mL; p < .001) and controls (0.6 +/- 0.3 ng/mL; p < 0.001). Active sCD154 can be derived from mast cell activation or other leukocytes. It is concluded that active sCD154 may be involved in the immune activation observed in patients with CIU.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176497

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  2 in total

Review 1.  Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review.

Authors:  Melanie Mitsui Wong; Paul Kevin Keith
Journal:  Allergy Asthma Clin Immunol       Date:  2020-08-04       Impact factor: 3.406

2.  Is delayed pressure urticaria associated with increased systemic release of sCD40L?

Authors:  T Jasinska; A Grzanka; E Machura; A Kasperska-Zajac
Journal:  Biomed Res Int       Date:  2013-10-23       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.